GleamWall
中文EN

FBLG FibroBiologics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1958777 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY11.3%
TTM EPS YoY169.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-1,696.9%
ROA-211.8%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets73.2%
Debt / equity0.00x
Current ratio1.22x
Interest coverage-71.97x

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-36.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$7.41M$4.50M
SG&A expense$9.24M$9.23M
Operating income-$16.65M-$13.74M
Interest expense$204,000$20,000
Income tax$0$0
Net income-$18.65M-$11.16M
EBITDA-$16.41M-$13.58M
EPS (basic)-0.42-0.34
EPS (diluted)-0.42-0.34
Weighted avg. shares (diluted)44.66M32.88M
Balance sheet
Cash & equivalents$4.89M$13.98M
Current assets$6.35M$14.23M
PP&E, net$842,000$824,000
Total assets$9.62M$16.45M
Current liabilities$1.76M$12.73M
Total liabilities$3.46M$13.71M
Shareholders' equity$6.16M$2.73M
Cash flow statement
Operating cash flow-$16.39M-$11.90M
Capital expenditure$262,000$184,000
Free cash flow-$16.66M-$12.09M
Investing cash flow-$262,000-$184,000
Financing cash flow$7.57M$16.91M
Depreciation & amortization$244,000$157,000
Stock-based compensation$2.69M$2.22M

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.